Welcome to the start of another year with *Seminars in Thrombosis & Hemostasis* (STH). This is my 7th year as editor-in-chief, and my 10th year of editorial association with this journal, having originally served as a regional editor. First, I sincerely wish to thank all the contributors to STH over the past years, as well as the guest editors for these issues, and of course, the current and past senior and associate editors of the journal. There will be some changes to the editorial team over the forthcoming 12 months, with an expansion of this team currently in plan. Also, Dr. Catherine Hayward has indicated she would like to step down from her role as senior editor. We sincerely thank her for her support in previous years and wish her continued success in her work. Last year represented a milestone for this journal, representing the 40th year of publication, a landmark that we celebrated with two special 40th anniversary celebratory issues.¹ ²

I will also take this opportunity to thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal. In particular, I would like to thank Subhankar De, the production editor for STH for managing the production process of STH issues and articles. I also wish to thank Kelly Coffey, a journals coordinator for Thieme Medical Publishers, as well as other key people at Thieme, some of who prefer to remain unnamed, for the additional support provided over the recent years.

This is also a fitting time to once again reflect on our journal’s impact factor, which was 3.693 for 2013. This represents a drop from our 2012 impact factor of 4.216 (►Fig. 1). I am hopeful that this pattern reflects some stabilization of the STH impact factor at around 4 over the coming years. It might be of some interest to note that the impact factor for most thrombosis and hemostasis focused journals fell in 2013 compared with 2012 values (►Fig. 2). The reason for this generalized fall in impact factor for thrombosis and hemostasis focused journals is unknown, although it could be at least in part due to continued development of additional publishing avenues from open access models. I have also previously highlighted,³ ⁴ and would continue to assert, that the impact factor is not the only marker of journal “quality” that we should consider, given the existence of other biometric markers and the limitations of any individual marker (including the impact factor) as a “quality” indicator.

Nevertheless, for the potential interest of the readership and contributing authors, I have listed the highest 2013-cited, 2010/2011-published, contributions from this journal in ►Table 1.⁵–⁶ These contributions identify those publications most contributing to the 2013 impact factor, and each was cited five or more times in 2013. The top

---

**Fig. 1** The impact factor for *Seminars in Thrombosis & Hemostasis*, from 2003 to 2013.

---

### Table 1

<table>
<thead>
<tr>
<th>Year</th>
<th>Impact Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>2.018</td>
</tr>
<tr>
<td>2004</td>
<td>2.077</td>
</tr>
<tr>
<td>2005</td>
<td>2.326</td>
</tr>
<tr>
<td>2006</td>
<td>3.086</td>
</tr>
<tr>
<td>2007</td>
<td>4.169</td>
</tr>
<tr>
<td>2008</td>
<td>4.534</td>
</tr>
<tr>
<td>2009</td>
<td>4.216</td>
</tr>
<tr>
<td>2010</td>
<td>3.693</td>
</tr>
<tr>
<td>2011</td>
<td>2.916</td>
</tr>
<tr>
<td>2012</td>
<td>1.906</td>
</tr>
</tbody>
</table>

---

Address for correspondence Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹
Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia
(e-mail: emmanuel.favaloro@health.nsw.gov.au).

Copyright © 2015 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.
ISSN 0094-6176.
Table 1 Most highly (2013) cited (2010/2011-published) contributions from Seminars in Thrombosis & Hemostasis

Table 1 (Continued)


Table 2  Current planned topics for future issues of Seminars in Thrombosis and Hemostasis

- Thrombosis and hemostasis issues in critically ill patients
- Anticoagulant therapy: present and future
- Current issues in hemophilia: recognizing clinical heterogeneity, replacement therapy, and outcome assessment
- Tissue factor in arterial and venous thrombosis. From pathophysiology to clinical implications
- Hemostatic dysfunction in liver diseases
- Hot topics VII (continuing series)
- Quality in thrombosis and hemostasis (continuing series)

Fig. 2 The relative change in impact factor (IF) from 2012 to 2013 for eight thrombosis and hemostasis-focused journals. Data shown as IF change from 2012 to 2013 in absolute terms (left axis; gray bars) and as a percentage change (right axis; hatched bars). The data for Seminars in Thrombosis & Hemostasis identified as STH.
20-listed articles were each actually cited 10 or more times in 2013. For those interested, the current listing can be compared with those of the most recently published top downloaded article listings from STH, the basis of the Eberhard Mammen "Most Popular" awards.63,64 Accordingly, I thank all the contributors, guest editors, and the editorial team for bringing us the content that makes STH.

Finally, a short note to confirm that we will continue to develop plans for the future content of this journal, and we are confident that we will be able to continue to bring you, the reader, the high-quality journal that you have come to expect. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in Table 2. At the same time, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises.

We look forward to another interesting year of reading in 2015!

References
18 Pengo V, Banzato A, Bion E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012;38(4):322–327
32 Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012;38(4):385–389